Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13466-13479

  Chirkova, Tatiana ^a   Boyoglu Barnum, Seyhan ^a   Gaston, Kelsey A ^a   Malik, Fahad M ^a   Trau, Steven P ^a   Oomens, Antonius G P ^b   Anderson, Larry J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE RECEPTOR CX3CR1; CX3C CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERFERON; MONOCLONAL ANTIBODY; PROTEIN CX4C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; CELL MEMBRANE PERMEABILITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RESPIRATORY EPITHELIUM; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; T LYMPHOCYTE SUBPOPULATION;

ADAPTIVE IMMUNITY; AMINO ACID MOTIFS; CHEMOKINES, CX3C; EPITHELIAL CELLS; HUMANS; IMMUNITY, INNATE; INTERFERONS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, CHEMOKINE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VIRAL PROTEINS;

EID: 84888023471     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01741-13     Document Type: Article

References (85)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446.
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children:a systematic review and meta-analysis. Lancet 375:1545-1555.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352:1749-1759.
4. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360:588-598.
5. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
6. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89:435-448.
7. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449-463.
8. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421.
9. Graham BS. 2011. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 239:149-166.
10. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL. 1986. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus:comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc. Natl. Acad. Sci. U.S.A. 83:7462-7466.
11. Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, Wertz GW. 1987. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61:3855-3861.
12. Connors M, Collins PL, Firestone CY, Murphy BR. 1991. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65:1634-1637.
13. Anderson LJ, Heilman CA. 1995. Protective and disease-enhancing immune responses to respiratory syncytial virus. J. Infect. Dis. 171:1-7.
14. Melero JA, Garcia-Barreno B, Martinez I, Pringle CR, Cane PA. 1997. Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. J. Gen. Virol. 78:2411-2418.
15. Collins PL, Crowe JE, Jr. 2007. Respiratory syncytial virus and metapneumovirus, p 1601-1646. In Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, Roizman B (ed), Fields virology, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
16. Trento A, Casas I, Calderon A, Garcia-Garcia ML, Calvo C, Perez-Brena P, Melero JA. 2010. Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. J. Virol. 84:7500-7512.
17. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2:732-738.
18. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L. 1998. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U.S.A. 95:10896-10901.
19. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. 1997. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91:521-530.
20. Bar-On L, Birnberg T, Lewis KL, Edelson BT, Bruder D, Hildner K, Buer J, Murphy KM, Reizis B, Jung S. 2010. CX3CR1+ CD8alpha+ dendritic cells are a steady-state population related to plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 107:14745-14750.
21. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O, Imai T. 2002. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 168:6173-6180.
22. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188:1413-1419.
23. Bembridge GP, Garcia-Beato R, Lopez JA, Melero JA, Taylor G. 1998. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. J. Immunol. 161:2473-2480.
24. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. 1996. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J. Virol. 70:7783-7791.
25. Johnson TR, Graham BS. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol. 73:8485-8495.
26. Shingai M, Azuma M, Ebihara T, Sasai M, Funami K, Ayata M, Ogura H, Tsutsumi H, Matsumoto M, Seya T. 2008. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFNbeta induction. Int. Immunol. 20:1169-1180.
27. Sparer TE, Matthews S, Hussell T, Rae AJ, Garcia-Barreno B, Melero JA, Openshaw PJ. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J. Exp. Med. 187:1921-1926.
28. Tebbey PW, Hagen M, Hancock GE. 1998. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J. Exp. Med. 188:1967-1972.
29. Arnold R, Konig B, Werchau H, Konig W. 2004. Respiratory syncytial virus deficient in solubleGprotein induced an increased proinflammatory response in human lung epithelial cells. Virology 330:384-397.
30. Ray R, Hoft DF, Meyer K, Brown R, Lagging LM, Belshe RB. 2001. Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus. Virus Res. 75:147-154.
31. Johnson TR, McLellan JS, Graham BS. 2012. Respiratory syncytial virus glycoproteinGinteracts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J. Virol. 86:1339-1347.
32. Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, Karron RA, Collins PL, Kleeberger SR. 2005. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl. Acad. Sci. U.S.A. 102:8996-9001.
33. Bukreyev A, Serra ME, Laham FR, Melendi GA, Kleeberger SR, Collins PL, Polack FP. 2006. The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J. Virol. 80:5854-5861.
34. Melendi GA, Bridget D, Monsalvo AC, Laham FF, Acosta P, Delgado MF, Polack FP, Irusta PM. 2011. Conserved cysteine residues within the attachmentGglycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses. Virus Genes 42:46-54.
35. Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA. 2009. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a Toll-like receptor pathway. Viral Immunol. 22:147-161.
36. Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, Anderson LJ. 2003. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J. Virol. 77:6580-6584.
37. Tripp RA, Jones L, Anderson LJ. 2000. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J. Virol. 74:6227-6229.
38. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, Murphy BR, Collins PL. 2008. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82:12191-12204.
39. Bukreyev A, Yang L, Collins PL. 2012. The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement. J. Virol. 86:10880-10884.
40. Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. 2006. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J. Immunol. 176:1600-1608.
41. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. 2003. Enhanced disease and pulmonary eosinophilia associated with formalininactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. 77:9831-9844.
42. Oshansky CM, Barber JP, Crabtree J, Tripp RA. 2010. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J. Infect. Dis. 201:1201-1207.
43. Konig B, Streckert HJ, Krusat T, Konig W. 1996. Respiratory syncytial virus G-protein modulates cytokine release from human peripheral blood mononuclear cells. J. Leukoc. Biol. 59:403-406.
44. Qin L, Hu CP, Feng JT, Xia Q. 2011. Activation of lymphocytes induced by bronchial epithelial cells with prolonged RSV infection. PLoS One 6:e27113. doi:10.1371/journal.pone.0027113.
45. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP. 1973. In vitro cultivation of human tumors:establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51:1417-1423.
46. Mitra R, Baviskar P, Duncan-Decocq RR, Patel D, Oomens AG. 2012. The human respiratory syncytial virus matrix protein is required for maturation of viral filaments. J. Virol. 86:4432-4443.
47. Anderson LJ, Hierholzer JC, Stone YO, Tsou C, Fernie BF. 1986. Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J. Clin. Microbiol. 23:475-480.
48. Anderson LJ, Hierholzer JC, Bingham PG, Stone YO. 1985. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 22:1050-1052.
49. Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, Schrag SJ, Taylor TH, Jr, Beall BW, Breiman RF, Feikin DR, Njenga MK, Mayer LW, Oberste MS, Tondella ML, Winchell JM, Lindstrom SL, Erdman DD, Fields BS. 2011. Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J. Clin. Microbiol. 49:2175-2182.
50. Prussin C, Metcalfe DD. 1995. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J. Immunol. Methods 188:117-128.
51. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80:4501-4509.
52. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFNlambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4:69-77.
53. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81:7749-7758.
54. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Jr, Lombard LA, Gray GS, Nadler LM. 1993. Cloning of B7-2:a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909-911.
55. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM. 1994. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 83:793-798.
56. Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C, Bardelli M, Montagna D, Locatelli F, Wack A. 2007. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 109:5371-5379.
57. Hart DN. 1997. Dendritic cells:unique leukocyte populations which control the primary immune response. Blood 90:3245-3287.
58. Kawai T, Akira S. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7:131-137.
59. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712.
60. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. 2008. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun. Ageing 5:6. doi:10.1186/1742 -4933-5-6.
61. Kauvar LM, Harcourt JL, Haynes LM, Tripp RA. 2010. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2:655-661.
62. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4:63-68.
63. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR. 2008. An important role for type III interferon (IFN-lambda/ IL-28) in TLR-induced antiviral activity. J. Immunol. 180:2474-2485.
64. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P. 2008. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4:e1000151. doi:10.1371/journal.ppat.1000151.
65. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4:e1000017. doi:10.1371/journal.ppat.1000017.
66. Okabayashi T, Kojima T, Masaki T, Yokota S, Imaizumi T, Tsutsumi H, Himi T, Fujii N, Sawada N. 2011. Type-III interferon, not type-I, is the predominant interferon induced by respiratory viruses in nasal epithelial cells. Virus Res. 160:360-366.
67. Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF. 2012. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc. Natl. Acad. Sci. U.S.A. 109:5040-5045.
68. Ioannidis I, McNally B, Willette M, Peeples ME, Chaussabel D, Durbin JE, Ramilo O, Mejias A, Flano E. 2012. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J. Virol. 86:5422-5436.
69. Lo MS, Brazas RM, Holtzman MJ. 2005. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J. Virol. 79:9315-9319.
70. Bossert B, Marozin S, Conzelmann KK. 2003. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. J. Virol. 77:8661-8668.
71. Spann KM, Tran KC, Collins PL. 2005. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J. Virol. 79:5353-5362.
72. Moore EC, Barber J, Tripp RA. 2008. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol. J. 5:116. doi:10.1186/1743 -422X-5-116.
73. Johnson TR, Johnson CN, Corbett KS, Edwards GC, Graham BS. 2011. Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus. PLoS One 6:e16458. doi:10.1371/journal.pone.0016458.
74. Guerrero-Plata A, Casola A, Suarez G, Yu X, Spetch L, Peeples ME, Garofalo RP. 2006. Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus. Am. J. Respir. Cell Mol. Biol. 34:320-329.
75. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. 2008. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J. Cereb. Blood Flow Metab. 28:1707-1721.
76. Liu H, Jiang D. 2011. Fractalkine/CX3CR1 and atherosclerosis. Clin. Chim. Acta 412:1180-1186.
77. Zhang J, Patel JM. 2010. Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases. Int. J. Clin. Exp. Med. 3:233-244.
78. Ross RJ, Zhou M, Shen D, Fariss RN, Ding X, Bojanowski CM, Tuo J, Chan CC. 2008. Immunological protein expression profile in Ccl2/ Cx3cr1 deficient mice with lesions similar to age-related macular degeneration. Exp. Eye Res. 86:675-683.
79. Ishida Y, Hayashi T, Goto T, Kimura A, Akimoto S, Mukaida N, Kondo T. 2008. Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J. Immunol. 181:4208-4218.
80. Tak PP, Firestein GS. 2001. NF-kappaB:a key role in inflammatory diseases. J. Clin. Invest. 107:7-11.
81. Fraticelli P, Sironi M, Bianchi G, D'Ambrosio D, Albanesi C, Stoppacciaro A, Chieppa M, Allavena P, Ruco L, Girolomoni G, Sinigaglia F, Vecchi A, Mantovani A. 2001. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 107:1173-1181.
82. Amanatidou V, Sourvinos G, Apostolakis S, Tsilimigaki A, Spandidos DA. 2006. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr. Infect. Dis. J. 25:410-414.
83. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D'Agostino RB, O'Donnell CJ, Patel DD, Murphy PM. 2003. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J. Clin. Invest. 111:1241-1250.
84. Lavergne E, Labreuche J, Daoudi M, Debre P, Cambien F, Deterre P, Amarenco P, Combadiere C. 2005. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol. 25:847-853.
85. Moatti D, Faure S, Fumeron F, Amara Mel W, Seknadji P, McDermott DH, Debre P, Aumont MC, Murphy PM, de Prost D, Combadiere C. 2001. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97:1925-1928.